focus -WSS

focus

author：knowledge 2025-09-30 20:34:43 - browse：5932

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Color Health wants to make cancer screenings convenient

WSS

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

CDC advisory group OKs chikungunya vaccine

Using force crossed my mind when examining a defiant young patient

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

entertainment

focus

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

10 states plan to sue EPA over standards for residential wood

Medical leaders decry Supreme Court decision on affirmative action

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

Trump demands the U.S. pay no more for drugs than other countries … again

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

Hepatitis C has a cure — but many Americans still lack access to it

10 states plan to sue EPA over standards for residential wood

How to save PrEP access — and even expand it

A timeline of the missing Titanic tourist submersible

focus

Neuroscience renaissance leads to new crop of psychiatric drugs

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

CDC panel: People 65 and older should get a Covid spring booster shot

Elisabeth Bik tackles the widespread issue of research misconduct

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

leisure time

knowledge

knowledge

focus